Tags

Type your tag names separated by a space and hit enter

Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation.
PDA J Pharm Sci Technol. 2011 May-Jun; 65(3):198-206.PJ

Abstract

Norfloxacin is a drug with an absorption window. Its oral bioavailability is 30-40% and is a case for improvement by appropriate formulation design. In our previous study, gastroretentive floating tablets for norfloxacin were developed employing three different polymers such as HPMC K4M, HPMC K100M, and xanthan gum. The purpose of this investigation is to further improve and evaluate the in vitro and in vivo performance of the prepared floating tablets by inclusion of citric acid as an acidifier, which is also useful in a fed state. The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. The effects of citric acid at different concentrations on drug release and floating properties were studied. All the prepared batches showed good in vitro buoyancy. It was observed that the tablets remained buoyant for 24 h. The best formulation (F4c), consisting of 1.5% citric acid and 18% HPMC K4M, was selected based on in vitro characteristics and used in vivo radiographic studies by incorporating barium sulphate. These studies revealed that the tablets remained in the stomach for 205 ± 8.4 min in fasting human volunteers. In vivo studies were carried out for the best formulation in eight healthy male human volunteers, and the pharmacokinetic parameters of the developed formulation were compared with marketed conventional (Norbid) tablets. Based on the in vivo performance in a two-way, crossover study design in healthy subjects, the developed floating tablets showed superior bioavailability than the Norbid tablets. The increased bioavailability of developed formulation was found to be 16.27%.

LAY ABSTRACT

Norfloxacin is a broad-spectrum antibiotic used to treat bacterial infections such as respiratory and urinary tract infections. Conventional norfloxacin tablets show incomplete drug absorption resulting in lower bioavailabilty. Norfloxacin is better absorbed in the stomach. The dosage forms that remain in the stomach are referred to as gastroretentive drug delivery systems. Gastroretentive floating tablets of norfloxcin were developed by employing three different polymers, which prolonged the drug release from the dosage forms. Tablet floatation was achieved by an effervescent mechanism. Citric acid at different concentrations was used in formulations to provide an acidic microenvironment. The prepared tablets were characterized for hardness, weight variation, thickness, friability, floating lag time, and dissolution. Around 12 tablet formulations were prepared as a continuation of the previous work. The best formulation (F4c) was selected based on in vitro characteristics and used in vivo radiographic studies by incorporating barium sulphate as a radio-opaque agent. The tablets remained in the stomach for about 205 ± 8.4 min. Bioavailability studies were conducted in healthy male human volunteers, and the pharmacokinetic parameters of the best formulation were compared with that of the marketed conventional (Norbid) tablet. The increased bioavailability of the developed formulation was found to be 16.27%.

Authors+Show Affiliations

University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22293231

Citation

Guguloth, Mohan, et al. "Development of Sustained Release Floating Drug Delivery System for Norfloxacin: in Vitro and in Vivo Evaluation." PDA Journal of Pharmaceutical Science and Technology, vol. 65, no. 3, 2011, pp. 198-206.
Guguloth M, Bomma R, Veerabrahma K. Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. PDA J Pharm Sci Technol. 2011;65(3):198-206.
Guguloth, M., Bomma, R., & Veerabrahma, K. (2011). Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. PDA Journal of Pharmaceutical Science and Technology, 65(3), 198-206. https://doi.org/10.5731/pdajpst.2011.00685
Guguloth M, Bomma R, Veerabrahma K. Development of Sustained Release Floating Drug Delivery System for Norfloxacin: in Vitro and in Vivo Evaluation. PDA J Pharm Sci Technol. 2011 May-Jun;65(3):198-206. PubMed PMID: 22293231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. AU - Guguloth,Mohan, AU - Bomma,Ramesh, AU - Veerabrahma,Kishan, PY - 2012/2/2/entrez PY - 2012/2/2/pubmed PY - 2016/4/23/medline SP - 198 EP - 206 JF - PDA journal of pharmaceutical science and technology JO - PDA J Pharm Sci Technol VL - 65 IS - 3 N2 - : Norfloxacin is a drug with an absorption window. Its oral bioavailability is 30-40% and is a case for improvement by appropriate formulation design. In our previous study, gastroretentive floating tablets for norfloxacin were developed employing three different polymers such as HPMC K4M, HPMC K100M, and xanthan gum. The purpose of this investigation is to further improve and evaluate the in vitro and in vivo performance of the prepared floating tablets by inclusion of citric acid as an acidifier, which is also useful in a fed state. The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. The effects of citric acid at different concentrations on drug release and floating properties were studied. All the prepared batches showed good in vitro buoyancy. It was observed that the tablets remained buoyant for 24 h. The best formulation (F4c), consisting of 1.5% citric acid and 18% HPMC K4M, was selected based on in vitro characteristics and used in vivo radiographic studies by incorporating barium sulphate. These studies revealed that the tablets remained in the stomach for 205 ± 8.4 min in fasting human volunteers. In vivo studies were carried out for the best formulation in eight healthy male human volunteers, and the pharmacokinetic parameters of the developed formulation were compared with marketed conventional (Norbid) tablets. Based on the in vivo performance in a two-way, crossover study design in healthy subjects, the developed floating tablets showed superior bioavailability than the Norbid tablets. The increased bioavailability of developed formulation was found to be 16.27%. LAY ABSTRACT: Norfloxacin is a broad-spectrum antibiotic used to treat bacterial infections such as respiratory and urinary tract infections. Conventional norfloxacin tablets show incomplete drug absorption resulting in lower bioavailabilty. Norfloxacin is better absorbed in the stomach. The dosage forms that remain in the stomach are referred to as gastroretentive drug delivery systems. Gastroretentive floating tablets of norfloxcin were developed by employing three different polymers, which prolonged the drug release from the dosage forms. Tablet floatation was achieved by an effervescent mechanism. Citric acid at different concentrations was used in formulations to provide an acidic microenvironment. The prepared tablets were characterized for hardness, weight variation, thickness, friability, floating lag time, and dissolution. Around 12 tablet formulations were prepared as a continuation of the previous work. The best formulation (F4c) was selected based on in vitro characteristics and used in vivo radiographic studies by incorporating barium sulphate as a radio-opaque agent. The tablets remained in the stomach for about 205 ± 8.4 min. Bioavailability studies were conducted in healthy male human volunteers, and the pharmacokinetic parameters of the best formulation were compared with that of the marketed conventional (Norbid) tablet. The increased bioavailability of the developed formulation was found to be 16.27%. SN - 1948-2124 UR - https://www.unboundmedicine.com/medline/citation/22293231/Development_of_sustained_release_floating_drug_delivery_system_for_norfloxacin:_in_vitro_and_in_vivo_evaluation_ L2 - http://journal.pda.org/cgi/pmidlookup?view=long&pmid=22293231 DB - PRIME DP - Unbound Medicine ER -